Antibiotic resistance patterns in invasive group B streptococcal isolates.
Antibiotics are used for both group B streptococcal (GBS) prevention and treatment. Active population-based surveillance for invasive GBS disease was conducted in four states during 1996-2003. Of 3813 case-isolates, 91.0% (3471) were serotyped, 77.1% (2937) had susceptibility testing, and 46.6% (3471) had both. All were sensitive to penicillin, ampicillin, cefazolin, cefotaxime, and vancomycin. Clindamycin and erythromycin resistance was 12.7% and 25.6%, respectively, and associated with serotype V (P < .001). Clindamycin resistance increased from 10.5% to 15.0% (X(2) for trend 12.70; P < .001); inducible clindamycin resistance was associated with the erm genotype. Erythromycin resistance increased from 15.8% to 32.8% (X(2) for trend 55.46; P < .001). While GBS remains susceptible to beta-lactams, resistance to alternative agents such as erythromycin and clindamycin is an increasing concern.
Castor
Mei L
ML
Infectious Disease Epidemiology, Prevention and Control Division, Minnesota Department of Health, Saint Paul, MN 55164, USA.
Whitney
Cynthia G
CG
Como-Sabetti
Kathryn
K
Facklam
Richard R
RR
Ferrieri
Patricia
P
Bartkus
Joanne M
JM
Juni
Billie A
BA
Cieslak
Paul R
PR
Farley
Monica M
MM
Dumas
Nellie B
NB
Schrag
Stephanie J
SJ
Lynfield
Ruth
R
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D015169:Colony Count, Microbial; D004305:Dose-Response Relationship, Drug; D024881:Drug Resistance, Bacterial; D006801:Humans; D008826:Microbial Sensitivity Tests; D015995:Prevalence; D011634:Public Health; D012703:Serotyping; D013290:Streptococcal Infections / Q000188:drug therapy*; D013292:Streptococcus agalactiae / Q000145:classification / Q000187:drug effects*
D000900:Anti-Bacterial Agents